Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

7 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03740295 (ClinicalTrials.gov)	October 5, 2018	5/10/2018	Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis	Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis	Multiple Sclerosis	Dietary Supplement: Coconut oil and epigallocatechin gallate;Other: Placebo	Fundación Universidad Católica de Valencia San Vicente Mártir	Valencian Institute of Neurorehabilitation Foundation	Completed	19 Years	65 Years	All	60	Phase 2	Spain
2	NCT02011451 (ClinicalTrials.gov)	December 2015	10/12/2013	Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis	Safety and Neuroprotective Effects of Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis	Multiple Sclerosis	Drug: 95% Pure ECGC capsules 200mg;Drug: Placebo Comparator:	Louisiana State University Health Sciences Center in New Orleans	National Multiple Sclerosis Society	Withdrawn	18 Years	65 Years	Both	0	Phase 2	United States
3	NCT01417312 (ClinicalTrials.gov)	July 2011	15/8/2011	Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients		Multiple Sclerosis, Relapsing-Remitting	Dietary Supplement: Capsules with 160 mg Teavigo (at least 94% EGCG);Dietary Supplement: Placebo	Charite University, Berlin, Germany	NULL	Completed	20 Years	60 Years	All	20	N/A	Germany
4	NCT00799890 (ClinicalTrials.gov)	May 2009	28/11/2008	Sunphenon in Progressive Forms of Multiple Sclerosis	Monocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Sunphenon EGCG;Drug: Placebo	Friedemann Paul	TAIYO EUROPE	Completed	18 Years	65 Years	All	61	Phase 2/Phase 3	Germany
5	NCT00525668 (ClinicalTrials.gov)	September 2007	4/9/2007	Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)	Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)	Relapsing-remitting Multiple Sclerosis	Drug: epigallocatechin -gallate (Sunphenon);Drug: placebo	Charite University, Berlin, Germany	NULL	Completed	18 Years	60 Years	All	120	Phase 1/Phase 2	Germany
6	EUCTR2006-006323-39-DE (EUCTR)	19/06/2007	05/03/2007	Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS	Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS	relapsing-remitting multiple sclerosisICD classification: G35.1	Product Name: Sunphenon Other descriptive name: Sunphenon EGCg TM	Charité-Universitätsmedizin Berlin	NULL	Not Recruiting			Female: yes Male: yes	100		Germany
7	EUCTR2008-005213-22-DE (EUCTR)		22/08/2008	SUPREMES - Sunphenon in progressive forms of multiple sclerosis	SUPREMES - Sunphenon in progressive forms of multiple sclerosis - SUPREMES	primary and secondary progressive forms of multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Sunphenon Other descriptive name: Sunphenon EGCg	Charite Universitätsmedizin Berlin	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2;Phase 3	Germany

先頭へ